We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Fidaxomicin in Healthy Male Japanese and Caucasian Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01813448
Recruitment Status : Completed
First Posted : March 19, 2013
Last Update Posted : May 21, 2014
Sponsor:
Collaborator:
Cubist Pharmaceuticals LLC
Information provided by (Responsible Party):
Astellas Pharma Inc ( Astellas Pharma Global Development, Inc. )

Brief Summary:
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics (PK) of single and multiple ascending doses of fidaxomicin in healthy subjects. This study will also compare the safety, tolerability and PK of single and multiple doses of fidaxomicin in healthy Japanese and Caucasian subjects.

Condition or disease Intervention/treatment Phase
Pharmacokinetics of Fidaxomicin Healthy Subjects Drug: Fidaxomicin Drug: Placebo Phase 1

Detailed Description:

Eligible subjects will check into the unit on Day-2 and remain confined to the clinical unit until Day 17.

Cohorts 2 and 3, which may run in parallel, will only be enrolled after review of the available safety data of Cohort 1 by the Safety Review Team.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 36 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Official Title: A Phase 1, Randomized, Double-Blind, Placebo-Controlled Dose Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Fidaxomicin in Healthy Male Japanese and Caucasian Subjects
Study Start Date : February 2013
Actual Primary Completion Date : April 2013
Actual Study Completion Date : April 2013

Resource links provided by the National Library of Medicine

Drug Information available for: Fidaxomicin

Arm Intervention/treatment
Experimental: Cohort 1: Fidaxomicin low dose in Japanese males Drug: Fidaxomicin
oral
Other Names:
  • OPT-80
  • Dificlir
  • Dificid

Experimental: Cohort 2: Fidaxomicin high dose in Japanese males Drug: Fidaxomicin
oral
Other Names:
  • OPT-80
  • Dificlir
  • Dificid

Experimental: Cohort 3: Fidaxomicin high dose in Caucasian males Drug: Fidaxomicin
oral
Other Names:
  • OPT-80
  • Dificlir
  • Dificid

Placebo Comparator: Matching Placebo in Caucasian males Drug: Placebo
oral

Placebo Comparator: Matching Placebo in Japanese males Drug: Placebo
oral




Primary Outcome Measures :
  1. Pharmacokinetics (PK) of fidaxomicin in plasma (single dose): Lag time (tlag) [ Time Frame: Days 1-5 (14 times) ]
  2. PK of fidaxomicin plasma (single dose): Time to attain maximum concentration (tmax) [ Time Frame: Days 1-5 (14 times) ]
  3. PK of fidaxomicin in plasma (single dose): Maximum Concentration (Cmax) [ Time Frame: Days 1-5 (14 times) ]
  4. PK of fidaxomicin in plasma (single dose): Area Under the Plasma Concentration - Time Curve (AUC) from Time Zero to Time of Last Measurable Concentration (AUClast) [ Time Frame: Days 1-5 (14 times) ]
  5. PK of fidaxomicin in plasma (single dose): AUC - Time Curve from Time Zero to Infinity (aucinf) [ Time Frame: Days 1-5 (14 times) ]
  6. PK of fidaxomicin in plasma (single dose): AUC - Time Curve from Time Zero to 12 hours (AUC 0-12h) [ Time Frame: Days 1-5 (14 times) ]
  7. PK of fidaxomicin in plasma (single dose): Total Body Clearance after Single Dose (CL/F) [ Time Frame: Days 1-5 (14 times) ]
  8. PK of fidaxomicin in plasma (single dose): Apparent Volume of Distribution During Terminal Phase (Vz/F) [ Time Frame: Days 1-5 (14 times) ]
  9. PK of fidaxomicin in plasma (last dose): Apparent Volume of Distribution During Terminal Phase (Vz/F) [ Time Frame: Days 15-17 (11 times) ]
  10. PK of fidaxomicin in plasma (single dose): Apparent Terminal elimination Half-life (t 1/2) [ Time Frame: Days 1-5 (14 times) ]
    Single Dose

  11. PK of fidaxomicin in plasma (last dose): Apparent Terminal elimination Half-life (t 1/2) [ Time Frame: Days 15-17 (11 times) ]
    Single Dose

  12. PK of fidaxomicin in plasma (single dose): Trough levels [ Time Frame: Days 6, 7, 10, and 12 (pre-morning dose) ]
  13. PK of fidaxomicin in plasma (last dose): tmax at Steady State (tmax, ss) [ Time Frame: Days 15-17 (11 times) ]
    Last Dose

  14. PK of fidaxomicin in plasma (last dose): Cmax at Steady State (Cmax, ss) [ Time Frame: Days 15-17 (11 times) ]
    Last Dose

  15. PK of fidaxomicin in plasma (last dose): AUC Over the dosing Interval (AUCtau) [ Time Frame: Days 15-17 (11 times) ]
  16. PK of fidaxomicin in plasma (last dose): CL/F at Steady State (CL/F ss) [ Time Frame: Days 15-17 (11 times) ]
  17. PK of fidaxomicin in plasma (last dose): Peak: Trough Ratio (PTR) [ Time Frame: Days 15-17 (11 times) ]
  18. PK of fidaxomicin in plasma (last dose): Accumulation Ratio (Racc) [ Time Frame: Days 15-17 (11 times) ]
  19. PK of fidaxomicin in plasma (last dose): Pre-dose Plasma Concentration Determined Directly from the Concentration-Time Profile (Ctrough) [ Time Frame: Days 15-17 (11 times) ]
  20. PK of fidaxomicin in urine (last dose): Cumulative Amount of Drug Excreted in the urine from Time Zero to Time of Last Measurable Concentration (Aelast) [ Time Frame: Days 1-5 (6 times) ]
  21. PK of fidaxomicin in urine (single dose): Percent Fraction of Administered Drug Excreted Unchanged in the urine from Time Zero to Time of Last Measurable Concentration (% Aelast ) [ Time Frame: Days 1-5 (6 times) ]
  22. PK of fidaxomicin in urine (single dose): Cumulative Amount of Drug Excreted in the Urine from time Zero to Infinity after Single Dose (Aeinf) [ Time Frame: Days 1-5 (6 times) ]
  23. PK of fidaxomicin in urine (single dose): Percent Fraction of administered drug excreted unchanged in the urine from time Zero to Infinity after Single Dose (% Aeinf) [ Time Frame: Days 1-5 (6 times) ]
  24. PK of fidaxomicin in urine (single dose): Renal Clearance (CL/R [ Time Frame: Days 1-5 (6 times) ]
  25. PK of fidaxomicin in urine (last dose): Cumulative Amount of Drug Excreted in the urine over the dosing Interval at Steady State (Aetau) [ Time Frame: Day 15 (1 time) ]
  26. PK of fidaxomicin in urine (last dose): Percent Fraction of Administered Drug Excreted Unchanged in the Urine over the Dosing Interval at Steady State (% Aetau) [ Time Frame: Day 15 (1 time) ]
  27. PK of fidaxomicin in urine (last dose): Renal Clearance at Steady State (CLR,ss) [ Time Frame: Day 15 ( 1 time) ]
  28. PK of fidaxomicin in feces (single dose): Amount of Drug Excreted in the Feces (Ae) [ Time Frame: Days 1-5 (5 times) ]
  29. PK of fidaxomicin in feces (last dose): Amount of Drug Excreted in the Feces (Ae) [ Time Frame: Days 15-17 (first bowel movement (BM) following the last dose to be collected) ]
  30. PK of fidaxomicin in feces (single dose): Percent Fraction of Administered Drug Excreted Unchanged in the Feces (%Ae) [ Time Frame: Days 1-5 (5 times) ]
  31. PK of fidaxomicin in feces (last dose): Percent Fraction of Administered Drug Excreted Unchanged in the Feces (%Ae) [ Time Frame: Days 15-17 (first BM following the last dose to be collected) ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years to 55 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Male subject and their female spouse/partners who are of childbearing potential must be using highly effective contraception consisting of two forms of birth control (one of which must be a barrier method) starting at Screening and continuing throughout the study period and for 90 days after final study drug administration
  2. Male subject must not donate sperm starting at Screening and throughout the study period and for at least 90 days after final study drug administration

    Inclusion Criteria for Japanese Subjects

  3. The subject is a healthy Japanese male who maintains the Japanese lifestyle, including diet and has a body mass index (BMI) of 18.0 to 28.0 kg/m2, inclusive.

    Inclusion Criteria for Caucasian Subjects

  4. The subject is a healthy Caucasian male and has a BMI of 18.0 to 32.0 kg/m2, inclusive

Exclusion Criteria:

  1. The subject has any clinically significant disease history
  2. The subject has a history of or current C.difficile infection or history of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs (history of appendectomy, hernia repair, and/or cholecystectomy is permitted)
  3. The subject has any clinically significant abnormality
  4. The subject has a resting (i.e., seated for 5 minutes) pulse <40 or >90 beats per minute (bpm) at Screening or Day -2
  5. The subject has hypertension (defined as seated systolic blood pressure [SBP] >140 mmHg or seated diastolic blood pressure [DBP] >90 mmHg) or hypotension (defined as seated SBP <90 mmHg or seated DBP <50 mmHg) at Screening or Day -2
  6. The subject has/had a symptomatic, viral, bacterial (including upper respiratory infection), or fungal (non-cutaneous) infection within 1 week prior to clinic check-in on Day -2
  7. The subject has a history of chronic diarrhea or constipation
  8. The subject has a positive result for hepatitis C antibodies or hepatitis B surface antigen at Screening or has a known positive history of human immunodeficiency virus (HIV)
  9. The subject has a known or suspected allergy or hypersensitivity to any of the components of fidaxomicin, the macrolide antibacterial class of compounds, or a history of multiple and/or severe allergies to drugs or foods or a history of severe anaphylactic reactions

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01813448


Locations
Layout table for location information
United States, California
Parexel
Glendale, California, United States, 91206
Sponsors and Collaborators
Astellas Pharma Global Development, Inc.
Cubist Pharmaceuticals LLC
Investigators
Layout table for investigator information
Study Director: Sr. Medical Director Astellas Pharma Global Development, Inc.
Additional Information:
Layout table for additonal information
Responsible Party: Astellas Pharma Global Development, Inc.
ClinicalTrials.gov Identifier: NCT01813448    
Other Study ID Numbers: 2819-CL-3001
First Posted: March 19, 2013    Key Record Dates
Last Update Posted: May 21, 2014
Last Verified: May 2014
Keywords provided by Astellas Pharma Inc ( Astellas Pharma Global Development, Inc. ):
Fidaxomicin
OPT-80
Healthy Subjects
Additional relevant MeSH terms:
Layout table for MeSH terms
Fidaxomicin
Anti-Bacterial Agents
Anti-Infective Agents